Forest plot showing the odds ratio (95% confidence interval) for each behavioral risk factor adjusted for other behavioral risk factors and demographic variables (age, gender, type of school, family history of glasses, mother’s education and socio-economic status).

<p>Forest plot showing the odds ratio (95% confidence interval) for each behavioral risk factor adjusted for other behavioral risk factors and demographic variables (age, gender, type of school, family history of glasses, mother’s education and socio-economic status).</p

Frequency of cases with quantum of myopia progression after 1 year.

<p>Frequency of cases with quantum of myopia progression after 1 year.</p

Incidence of myopia according to age.

<p>Incidence of myopia according to age.</p

Age specific incidence of myopia (n = 8200).

<p>Age specific incidence of myopia (n = 8200).</p

Progression of myopia according to age.

<p>Progression of myopia according to age.</p

Distribution of age, gender and type of school with incidence and progression of myopia.

<p>Distribution of age, gender and type of school with incidence and progression of myopia.</p

The mean and range of the hours spent per week in various behavioral risk factors among children with progression.

<p>The mean and range of the hours spent per week in various behavioral risk factors among children with progression.</p

Age specific progression of myopia (n = 1279).

<p>Age specific progression of myopia (n = 1279).</p

Age distribution of mean hours spent in reading / writing and outdoor activity.

<p>Age distribution of mean hours spent in reading / writing and outdoor activity.</p

A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease

Chemokine receptor 9 (CCR9), a cell surface chemokine receptor which belongs to the G protein-coupled receptor, 7-trans-membrane superfamily, is expressed on lymphocytes in the circulation and is the key chemokine receptor that enables these cells to target the intestine. It has been proposed that CCR9 antagonism represents a means to prevent the aberrant immune response of inflammatory bowel disease in a localized and disease specific manner and one which is accessible to small molecule approaches. One possible reason why clinical studies with vercirnon, a prototype CCR9 antagonist, were not successful may be due to a relatively poor pharmacokinetic (PK) profile for the molecule. We wish to describe work aimed at producing new, orally active CCR9 antagonists based on the 1,3-dioxoisoindoline skeleton. This study led to a number of compounds that were potent in the nanomolar range and which, on optimization, resulted in several possible preclinical development candidates with excellent PK properties